{
    "clinical_study": {
        "@rank": "45257", 
        "acronym": "iTOP", 
        "brief_summary": {
            "textblock": "This is a non-interventional observational study of patients receiving natalizumab\n      (TYSABRI\u00ae) in Ireland.  Time perspective of this study is both prospective and\n      retrospective.\n\n      The primary objective of this study is to assess the long-term safety (incidence and pattern\n      of SAEs including infections and discontinuations) in patients receiving natalizumab\n      (TYSABRI\u00ae) in a clinical practice setting.\n\n      The secondary objectives are to assess the long-term disease activity and progression of\n      patients with relapsing remitting multiple sclerosis (RRMS) who are receiving natalizumab\n      (TYSABRI\u00ae) in a clinical practice setting."
        }, 
        "brief_title": "Ireland TYSABRI\u00ae (Natalizumab) Observational Program (iTOP)", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multiple Sclerosis, Relapsing-Remitting", 
            "Relapsing Remitting Multiple Sclerosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Must give written informed consent and provide all authorizations required by local\n             law\n\n          2. Decision to treat with natalizumab (TYSABRI\u00ae) must precede enrollment\n\n        Patient characteristics and contraindications to treatment with natalizumab (TYSABRI\u00ae) in\n        accordance with prescribing information\n\n          1. Patients must be receiving natalizumab (Tysabri\u00ae) for the treatment of Relapsing\n             Remitting Multiple Sclerosis (RRMS) in accordance with the natalizumab (Tysabri\u00ae)\n             indication statement\n\n          2. Patient must have a documented diagnosis of Relapsing Remitting Multiple Sclerosis\n             (RRMS)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with Relapsing Remitting Multiple Sclerosis (RRMS) who are being treated with\n        natalizumab (TYSABRI\u00ae) and patients who meet the criteria defined in the indication\n        statement for prescription in Ireland. Existing patients will be enrolled retrospectively.\n        New patients will be enrolled after the decision to treat with natalizumab (TYSABRI\u00ae) has\n        been made."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943526", 
            "org_study_id": "TYS-IRL-11-4"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ireland", 
            "Natalizumab"
        ], 
        "lastchanged_date": "September 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tralee", 
                        "country": "Ireland", 
                        "state": "Kerry"
                    }, 
                    "name": "Biogen Idec Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cork", 
                        "country": "Ireland"
                    }, 
                    "name": "Biogen Idec Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "Biogen Idec Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Ireland TYSABRI\u00ae (Natalizumab) Observational Program (iTOP)", 
        "overall_contact": {
            "email": "medinfo-uk@biogenidec.com", 
            "last_name": "Medical Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Ireland: Irish Medicines Board", 
                "Ireland: Research Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The number of participants that experience serious adverse events (SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943526"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Participants Whose Multiple Sclerosis Progresses at least 1 Point on the Expanded Disability Status Score (EDSS) and Sustained Over 6 Months", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Proportion of Participants that Reach Expanded Disability Status Score (EDSS) Milestones Indicating Increasing Disability", 
                "safety_issue": "No", 
                "time_frame": "Up t o 3 years"
            }, 
            {
                "measure": "Proportion of Participants Whose Expanded Disability Status Score (EDSS) Worsened, Stabilized or Improved and Sustained over 6 Months", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Annualized Relapse Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Distribution of the Total Number of Relapses During the Study", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Time to First Relapse", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Proportions of Participants with relapse", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Multiple Sclerosis (MS) Disability Progression and MS Disease Activity Summarized for Subpopulations According to Baseline Characteristics", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}